Renalytix
Renalytix is an artificial intelligence-enabled in vitro diagnostics company focused on the clinical management of chronic kidney disease.
Its blood-based test combines biomarker analysis with machine learning to generate a five-year kidney function decline risk score in adults with type 2 diabetes and CKD stages 1 to 3b.
Renalytix serves healthcare providers across the United States and has partnered with Tempus AI to expand access through integrated electronic health record systems.
Latest News
Renalytix Chair Julian Baines to Step Down on 31 December
Renalytix has announced that Julian Baines will step down as Non-Executive Chair on 31 December 2026, having rejoined the board in November 2024. The company is interviewing senior industry executives as potential successors and expects to present recommendations to the board shortly.
Renalytix signs multi-year Quest Diagnostics agreement
Renalytix has signed a multi-year agreement with Quest Diagnostics to expand US access to its kidneyintelX.dkd blood test, with availability through Quest's specimen collection and connectivity network targeted for early 2027. Renalytix will continue to run the assay at its New York laboratory and handle billing, while the deal also gives Quest an option to in-license the test after specified commercialisation milestones.